Pruritus Clinical Trial
Official title:
Effect of Long Acting Antihistamine on Opioid- Induced Pruritus: A Double-blind Placebo Controlled Study
Verified date | September 2018 |
Source | Virginia Commonwealth University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is determine if long acting antihistamine like cetirizine can help with itching induced by opioid pain medications.
Status | Terminated |
Enrollment | 3 |
Est. completion date | November 2017 |
Est. primary completion date | November 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 18 Years |
Eligibility |
Inclusion Criteria: - Children age 6-18yrs on opioids who develop pruritus and are willing to participate in the study Exclusion Criteria: - Children with history of chronic urticaria - Children with other chronic pruritic condition like eczema, contact dermatitis, psoriasis - Children with known hypersensitivity to cetirizine/zyrtec - Children on H1 antihistamine like diphenhydramine, hydroxyzine, cetirizine, loratadine, fexofenadine, chlorpheniramine within the last 7days prior to randomization - Children who have received Ondansetron within 24hrs prior to randomization - Children who are on Tricyclic antidepressants - Children who are unwilling or unable to swallow the capsule. - Children with chronic liver or kidney disease |
Country | Name | City | State |
---|---|---|---|
United States | Children's Hospital of Richmond at VCU | Richmond | Virginia |
Lead Sponsor | Collaborator |
---|---|
Virginia Commonwealth University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Itch Score | Itch score will be used to analyze our primary outcome. The subjects will have an itch score at baseline and compared to itch score at 3hrs post intervention. Itch score is measured on a scale of 1 to 4, with lower scores indicating less itchiness. | Baseline to 3 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05038982 -
Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
|
Phase 2 | |
Completed |
NCT04510090 -
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
|
Phase 1 | |
Completed |
NCT02143973 -
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
|
Phase 2/Phase 3 | |
Completed |
NCT01236859 -
Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus
|
N/A | |
Completed |
NCT00782054 -
Evaluation of Post Burn Rehabilitation Population for Itch Control
|
Phase 4 | |
Completed |
NCT04999787 -
A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of HSK21542 Injection in Liver Disease Subjects With Pruritus
|
Phase 2 | |
Recruiting |
NCT04256759 -
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
|
Phase 2 | |
Completed |
NCT04337073 -
The Effect of Propofol on Dexamethasone-induced Perineal Pruritus
|
Early Phase 1 | |
Completed |
NCT04415034 -
Scalp Pruritus Measurement Using Visual Analog Scale and 5-d Itch Scale in Children With Pediculosis Capitis
|
||
Active, not recruiting |
NCT05525520 -
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
|
Phase 2 | |
Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
Completed |
NCT04399525 -
Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.
|
N/A | |
Recruiting |
NCT02432508 -
Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis
|
N/A | |
Completed |
NCT02653703 -
L-menthol as a Topical Counter-irritant to TRPA1-induced Neurogenic Inflammation and Pain
|
N/A | |
Completed |
NCT01963793 -
Topical Aprepitant in Prurigo Patients
|
Phase 2 | |
Completed |
NCT01232985 -
Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults
|
Phase 2 | |
Not yet recruiting |
NCT00577967 -
Gabapentin - A Solution to Uremic Pruritus?
|
N/A | |
Recruiting |
NCT06120907 -
Swiss Itch Registry
|
||
Recruiting |
NCT04589429 -
Adding Nalbuphine for Control of Intrathecal Morphine Pruritus
|
Phase 2 | |
Completed |
NCT03322137 -
Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris
|
Phase 2 |